Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 8/20 | 0.42 |
| ▸ | HTR2B | P41595 | 7/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7254526 | 0.91 | ASIC3 (0.44) | ADRA2AADRA2BADRA2CHRH3DRD2 | |
| SCHEMBL9053084 | 0.81 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CHRH3HTR2C | |
| Hydrochloric Acid SCHEMBL7283443 | 0.80 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CHRH3HTR2C | |
| Trifluoroacetic Acid SCHEMBL4915477 | 0.75 | DRD2 (0.59) | HTR2CHTR2BDRD2DRD1HTR2A | |
| SCHEMBL6952795 | 0.73 | ASIC3 (0.50) | ADRA2AADRA2BADRA2CHRH3DRD2 | |
| SCHEMBL21762585 | 0.72 | HRH3 (0.54) | ADRA2AADRA2BADRA2CHRH3HTR2C | |
| SCHEMBL21753264 | 0.72 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CHRH3HTR2C | |
| SCHEMBL3252072 | 0.72 | PNMT (0.50) | ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL21753240 | 0.71 | HRH3 (0.52) | ADRA2AADRA2BADRA2CHRH3HTR2C | |
| Trifluoroacetic Acid SCHEMBL31013843 | 0.71 | HRH3 (0.61) | HRH3HTR2CHTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| EP-1735299-A1 | TERTRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097778-A1 | TETRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | HRH3, HRH4, HRH1 | ADRA2A 172/4885ADRA2B 102/4885ADRA2C 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.